Pallavi Chandra, PhD

Pallavi Chandra, PhD

Instructor in Medicine

Dr. Chandra specializes in Mycobacterium tuberculosis pathogenesis, with a special focus on immunometabolism. In recent work, she characterized a novel relationship between macrophage fatty acid metabolism and antimycobacterial immunity. In addition, she investigated metabolic perturbations in infected macrophages and found a unique co-metabolite that accumulates in clinical samples of tuberculosis patients. Her research goal is to investigate host pathways that enhance immunity to M. tuberculosis, which will contribute to biomarker development and establish rational strategies for combinatorial therapies.

  • BSc in Biochemistry at Sri Venkateswara College, University of Delhi, India. (2007)
  • MS in Biomedical Sciences, B.R. Ambedkar Center for Biomedical Research. (2009)During this time she worked with Dr. Munia Ganguli at IGIB, New Delhi for her dissertation where she studied development of peptide-based nanoparticles for gene delivery.
  • PhD Life Sciences, International Center for Genetic Engineering and Biotechnology, New Delhi, India. (2014)
Related links

Potts Memorial Foundation fellowship (2017-2019)

  • Merck Merck Millipore India Innovation Award (MMIIA) for the work titled Express Path Analysis Identifies a Tyrosine Kinase Src-centric Network Regulating Divergent Host Responses to Mycobacterium tuberculosis Infection. (2012)
  • University gold medal, University of Delhi, India (2009)
  • “Catch Them Young” scholarship, Council for Scientific and Industrial Research (CSIR) (2007-2009)
  • Patents
    Provisional patent 63/153,015, “Compositions and Methods for the Detection of Tuberculosis”. This was filed by Washington University. I am a co-inventor.

    US Patent PCT/US2019/022457, “Host Fatty Acid Oxidation Inhibitors as Antimicrobials”, Mar 15, 2019. This patent was filed by Washington University. I am a co-inventor.
Selected Publications

1. Chandra P*, Coullon H*, Agarwal M, Goss CW, Philips JA. Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection. J Clin Invest. 2022;132(3):e152509. doi: 10.1172/JCI152509. PMID: 35104812; PMCID: PMC8803325. *co-first authors

2. Chandra P, He L, Zimmerman M, Yang G, Köster S, Ouimet M, Wang H, Moore KJ, Dartois V, Schilling JD, Philips JA. Inhibition of Fatty Acid Oxidation Promotes Macrophage Control of Mycobacterium tuberculosis. mBio. 2020;11(4):e01139-20. doi: 10.1128/mBio.01139-20. PMID: 32636249; PMCID: PMC7343992.

3. Chandra P, Ghanwat S, Matta SK, Yadav SS, Mehta M, Siddiqui Z, Singh A, Kumar D. Mycobacterium tuberculosis Inhibits RAB7 Recruitment to Selectively Modulate Autophagy Flux in Macrophages. Sci Rep. 2015;5:16320. doi: 10.1038/srep16320. PMID: 26541268; PMCID: PMC4635374.

View publications on »